COMMUNIQUÉS West-GlobeNewswire

-
Lirum Therapeutics Announces New LX-101 Data in Thyroid Eye Disease Selected for Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
07/05/2025 -
Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance
07/05/2025 -
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
07/05/2025 -
Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting
07/05/2025 -
Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
07/05/2025 -
LifeStance Reports First Quarter 2025 Results
07/05/2025 -
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025
07/05/2025 -
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025
07/05/2025 -
Isarna Therapeutics Presents Positive Phase 2 BETTER Trial Final Results at ARVO 2025
07/05/2025 -
European Commission approves TREMFYA® (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease
07/05/2025 -
Oculis to Present at Upcoming May Investor Conferences
07/05/2025 -
Oculis to Present at Upcoming May Investor Conferences
07/05/2025 -
Prime Biome Reviews Fixed What Doctors Couldn’t – In Just Weeks! A Reality Based, Self Trial, Facts and Figure Which Revealed the Truth!
07/05/2025 -
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
07/05/2025 -
Yaqrit’s HE candidates set for phase 3 as company shows underpinning data at EASL
07/05/2025 -
Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis
07/05/2025 -
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
07/05/2025 -
Bluejay Therapeutics Reports First Preclinical Data for Liver-Targeted Fatty Acid Synthase (FASN) Inhibitor BJT-188 Being Investigated for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
07/05/2025 -
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis
07/05/2025
Pages